CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $22.20.

A number of equities research analysts have recently commented on CBLL shares. Canaccord Genuity Group dropped their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th.

Insider Buying and Selling

In other CeriBell news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the transaction, the insider directly owned 3,765,054 shares in the company, valued at approximately $75,752,886.48. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William W. Burke sold 2,207 shares of CeriBell stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the completion of the sale, the director owned 23,022 shares in the company, valued at approximately $456,756.48. This trade represents a 8.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 350,789 shares of company stock worth $6,946,191 in the last 90 days. 20.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CeriBell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new stake in shares of CeriBell in the fourth quarter valued at approximately $21,930,000. Royce & Associates LP acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $11,695,000. Adage Capital Partners GP L.L.C. purchased a new position in CeriBell during the fourth quarter worth approximately $10,965,000. Finally, JPMorgan Chase & Co. grew its holdings in CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares in the last quarter.

CeriBell Stock Performance

CeriBell stock traded up $0.09 during mid-day trading on Thursday, hitting $17.82. The company had a trading volume of 23,609 shares, compared to its average volume of 328,533. The company has a market capitalization of $675.99 million, a price-to-earnings ratio of -10.93 and a beta of 0.77. CeriBell has a 12-month low of $10.85 and a 12-month high of $24.33. The company’s fifty day moving average is $18.59 and its 200-day moving average is $19.31. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. Equities research analysts predict that CeriBell will post -1.69 EPS for the current year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.